Stock data
Cognition Therapeutics, Inc. (CGTX)
Cognition Therapeutics, Inc. (CGTX) reported net income of -US$23.49M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$47.80M | -US$23.49M | — |
| 2024 | — | — | -US$53.97M | -US$33.97M | — |
| 2023 | — | — | -US$50.72M | -US$25.79M | — |
| 2022 | — | — | -US$43.55M | -US$21.40M | — |
| 2021 | — | — | -US$28.60M | -US$11.72M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$3.93M | — |
| 2026-03-31 | — | -US$4.57M | — |
| 2025-12-31 | — | -US$3.34M | — |
| 2025-09-30 | — | -US$4.93M | — |
| 2025-06-30 | — | -US$6.73M | — |
| 2025-03-31 | — | -US$8.48M | — |
| 2024-12-31 | — | -US$7.84M | — |
| 2024-09-30 | — | -US$9.94M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.